Lemoli RM; Salvestrini V; Bianchi E; Bertolini F; Fogli M; Amabile M; Tafuri A; Salati S; Zini R; Testoni N; Rabascio C; Rossi L; Martin-Padura I; Castagnetti F; Marighetti P; Martinelli G; Baccarani M; Ferrari S; Manfredini R., Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib., «BLOOD», 2009, 114(25), pp. 5191 - 5200 [Scientific article]
Rosti G; Palandri F; Castagnetti F; Breccia M; Levato L; Gugliotta G; Capucci A; Cedrone M; Fava C; Intermesoli T; Cambrin GR; Stagno F; Tiribelli M; Amabile M; Luatti S; Poerio A; Soverini S; Testoni N; Martinelli G; Alimena G; Pane F; Saglio G; Baccarani M; GIMEMA CML Working Party., Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia., «BLOOD», 2009, 114, pp. 4933 - 4938 [Scientific article]
Follo MY; Finelli C; Mongiorgi S; Clissa C; Bosi C; Testoni N; Chiarini F;
Ramazzotti G; Baccarani M; Martelli AM; Manzoli L; Martinelli G; Cocco L, Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS., «PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA», 2009, 106, pp. 16811 - 16816 [Scientific article]
Castagnetti F; Palandri F; Amabile M; Testoni N; Luatti S; Soverini S; Iacobucci I; Breccia M; Rege Cambrin G; Stagno F; Specchia G; Galieni P; Iuliano F; Pane F; Saglio G; Alimena G; Martinelli G; Baccarani M; Rosti G., Results of high-dose imatinib mesylate in intermediate SOKAL risk chronic myeloid leukemia patients in early chronic phase: A phase II trial of the GIMEMA CML WP, «BLOOD», 2009, 113(15), pp. 3428 - 3434 [Scientific article]
Palandri F; Castagnetti F; Alimena G; Testoni N; Breccia M; Luatti S; Rege-Cambrin G; Stagno F; Specchia G; Martino B; Levato L; Merante S; Liberati AM; Pane F; Saglio G; Alberti D; Martinelli G; Baccarani M; Rosti G., The long-term durability of cytogenetic response in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up, «HAEMATOLOGICA», 2009, 94(2), pp. 205 - 212 [Scientific article]
Palandri F; Iacobucci I; Soverini S; Castagnetti F; Poerio A; Testoni N; Alimena G; Breccia M; Rege-Cambrin G; Tiribelli M; Varaldo R; Abruzzese E; Martino B; Luciano L; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G., Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response, «CLINICAL CANCER RESEARCH», 2009, 15, pp. 1059 - 1063 [Scientific article]
Luatti S.; Marzocchi G.; Ottaviani E.; Baldazzi C.; Stacchini M.; Gamberini C.; Salmi F.; Martinelli G.; Baccarani M.; Testoni N., Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications, «LEUKEMIA RESEARCH», 2008, 32, pp. 1941 - 1943 [Scientific article]
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G; GIMEMA Working Party on Chronic Myeloid Leukemia, Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up, «HAEMATOLOGICA», 2008, 93(12), pp. 1792 - 1796 [Scientific article]
Tosi P; Terragna C; Testoni N; Zamagni E; Renzulli M; Tacchetti P; Montanari E; Perrone G; Ceccolini M; Brioli A; Pallotti MC; Tura S; Baccarani M; Cavo M., Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation., «EUROPEAN JOURNAL OF HAEMATOLOGY», 2008, 80, pp. 31 - 36 [Scientific article]
Palandri F; Iacobucci I; Castagnetti F; Testoni N; Poerio A; Amabile M; Breccia M; Intermesoli T; Iuliano F; Rege-Cambrin G; Tiribelli M; Miglino M; Pane F; Saglio G; Martinelli G; Rosti G; Baccarani M; GIMEMA Working Party on CML., Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome, «HAEMATOLOGICA», 2008, 93(5), pp. 770 - 774 [Scientific article]
Palandri F; Iacobucci I; Martinelli G; Amabile M; Poerio A; Testoni N; Soverini S; Castagnetti F; De Vivo A; Breccia M; Specchia G; Abruzzese E; Martino B; Cilloni D; Saglio G; Pane F; Liberati AM; Rosti G; Baccarani M; GIMEMA Working Party on CML., Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML., «JOURNAL OF CLINICAL ONCOLOGY», 2008, 26, pp. 106 - 111 [Scientific article]
Palmisano M; Grafone T; Renzulli M; Ottaviani E; Testoni N; Paolini S; Papayannidis C; Baccarani M; Martinelli G, Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia., «HEMATOLOGY», 2008, 13(1), pp. 1 - 12 [Scientific article]
V. Papa; P.L. Tazzari; F. Chiarini; A. Cappellini; F. Ricci; A.M. Billi; C. Evangelisti; E. Ottaviani; G. Martinelli; N. Testoni; J.A. McCubrey; A.M. Martelli, Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells, «LEUKEMIA», 2008, 22, pp. 147 - 160 [Scientific article]
Lo-Coco F.; Cuneo A.; Pane F.; Cilloni D.; Diverio D.; Mancini M.; Testoni N.; Bardi A.; Izzo B.; Bolli N.; La Starza R.; Fazi P.; Iacobelli S.; Piciocchi A.; Vignetti M.; Amadori S.; Mandelli F.; Pelicci PG; Mecucci C.; Falini B.; Saglio G.; Acute Leukemia Working Party of the GIMEMA group, Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia, «HAEMATOLOGICA», 2008, 93, pp. 1017 - 1024 [Scientific article]
Malagola M; Damiani D; Martinelli G; Michelutti A; Cesana B; Vivo AD;
Piccaluga PP; Ottaviani E; Candoni A; Geromin A; Tiribelli M; Fanin R; Testoni N; Lauria F; Bocchia M; Gobbi M; Pierri I; Zaccaria A; Zuffa E; Mazza P; Priccolo G; Gugliotta L; Bonini A; Visani G; Skert C; Bergonzi C; Roccaro AM; Fili C; Baccarani M; Russo D., Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients., «BRITISH JOURNAL OF HAEMATOLOGY», 2007, 136, pp. 87 - 95 [Scientific article]
